OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

OKYO Pharma Ltd (NASDAQ:OKYO) announced connected Monday that it has filed its yearly study connected Form 20-F for the fiscal twelvemonth ended March 31, 2026, with the US Securities and Exchange Commission, portion outlining its fiscal presumption and advancement toward a planned Phase 3 objective proceedings for its pb cause candidate.

The clinical-stage biopharmaceutical institution said the yearly study is disposable done the SEC and its capitalist relations website.

Alongside the filing, OKYO highlighted its caller financing activities, noting it raised astir $25 cardinal during the fiscal year, including a February 2026 nationalist offering that generated astir $22 cardinal successful gross proceeds, including the workout of an overallotment option.

"We are pleased to denote the filing of our yearly report, which reflects important advancement crossed our operations," Chief Financial Officer Keeren Shah wrote successful the release.

"During the twelvemonth we raised astir $25 million, including the caller superior rise backed by renowned concern funds, which has strengthened our currency presumption and provides america with ample fiscal resources to implicit the NEPTUNE Phase 3 pivotal proceedings for urcosimod. This advances america toward imaginable registration, creating semipermanent worth for patients and shareholders."

The institution reported currency and currency equivalents of astir $20.6 cardinal arsenic of the extremity of March 2026, which it said is expected to money operations done completion of the planned planetary Phase 3 pivotal proceedings for urcosimod, its investigational attraction for neuropathic corneal pain.

OKYO plans to statesman the Phase 3 NEPTUNE proceedings successful the 2nd fractional of 2026. The survey is expected to enroll astir 111 patients crossed the US and Europe, with participants randomized successful a 2:1 ratio to person either 0.05% urcosimod oregon placebo successful a single-dose regimen

The institution said the proceedings plan follows affirmative feedback from the US Food and Drug Administration during a Type D gathering and is intended to service arsenic a imaginable registrational survey that could enactment a single-trial support pathway.